Emerging Antiviral Drugs for Hepatitis C Virus

Author(s): Masaru Enomoto, Akihiro Tamori, Norifumi Kawada

Journal Name: Reviews on Recent Clinical Trials

Volume 4 , Issue 3 , 2009

Become EABM
Become Reviewer
Call for Editor


Infection with hepatitis C virus (HCV) is a global health problem that affects approximately 170 million people worldwide. The current standard therapy with peginterferon alpha plus ribavirin for 48 weeks results in a sustained virologic response in less than 50% of patients with chronic hepatitis C genotype 1-the most prevalent type of HCV in North America and Europe. Development of new antiviral medicines has been hampered by the lack of an effective cell culture system and small-animal model. Herein we review recent progress in the development of new treatments under investigation in clinical trials, including specifically targeted antiviral therapy for HCV such as NS3/4A protease and NS5B polymerase inhibitors.

Keywords: Hepatitis C virus, interferon, polymerase inhibitor, protease inhibitor, ribavirin, STAT-C

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [179 - 184]
Pages: 6
DOI: 10.2174/157488709789957628
Price: $65

Article Metrics

PDF: 3